ClinicalTrials.gg

Program

KPCXM18

A development code. Also written as “The KPCXM18 injection”.

Its studies are mostly in Ischemic Stroke · Stroke, led by Kunming Pharmaceuticals.

Furthest: phase 2, since Feb 16, 20233 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kunming Pharmaceuticals31 open or runningphase 2since Feb 16, 2023Nov 3, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2020First study: phase 1 study in StrokeFirst studyNCT04629287 · 102 enrolled
  2. Feb 16, 2023Phase 2 study in Ischemic StrokeNCT05745311 · 240 enrolled
  3. Nov 23, 2025Phase 2 study in Ischemic StrokeNCT07279493 · 300 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07279493Ischemic Stroke · China2RecruitingOct 18, 2026300
NCT05745311Ischemic Stroke2UNKNOWNMay 1, 2024240
NCT04629287Stroke1UNKNOWNDec 2021102

How it is read

Names in the registry

  • “The KPCXM18 injection”, 3 entries
  • “KPCXM18”, 1 entry

Codes read as this program: KPCXM18.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.